Compare MasterCard Inc (MA) vs Oscar Health Inc (OSCR) Price & Performance

Mastercard (MA) trades at $543.19, down 0.08% on the day, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue grew to $32.79 billion in 2025, while net income margin remained high at 45.88%. Analysts maintain a strong buy consensus with a $634.27 price target, reflecting confidence in continued payment volume growth and digital expansion initiatives.

The stock presents a compelling growth opportunity given its consistent profitability, expanding cash flows, and leadership in digital payments. Key risks include competitive disruption from stablecoins and regulatory scrutiny. With zero sell ratings and 79% buy recommendations, Wall Street sentiment is overwhelmingly positive, though investors should monitor execution on AI and emerging market strategies against valuation multiples above sector averages.

Oscar Health (OSCR) trades at $29.60, up 1.72% today, showing mixed signals with a bullish technical trend but bearish oscillators. The company reported revenue growth to $11.70B in 2025, though net income remains negative at -$443.15M. Recent earnings beat expectations in Q1 2026 with EPS of $2.07, while analyst sentiment is divided with a consensus price target of $24.67. Positive cash flow trends and media coverage highlight growth potential amid ongoing profitability challenges.

Outlook: OSCR offers growth exposure in health insurance with strong revenue expansion and cash flow, but profitability risks persist. Investment opportunity lies in execution toward breakeven, while risks include margin pressure and competitive threats. The stock's current price above consensus target suggests cautious optimism is warranted.